{"transactions":[{"id":741793,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39305,"kind":"person","name":"Shiff Susan Ph.D.","position":1,"cik":"0001811463","reported_name":"Shiff Susan Ph.D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T20:30:29.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":2.78,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001811463-26-000002","document":"form4-06112026_040609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811463/000181146326000002/form4-06112026_040609.xml","form_type":"4"}},{"id":741332,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":35382,"kind":"person","name":"Smith Cynthia","position":1,"cik":"0001609480","reported_name":"Smith Cynthia","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T20:30:26.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":2.78,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001609480-26-000002","document":"form4-06112026_040607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000160948026000002/form4-06112026_040607.xml","form_type":"4"}},{"id":741331,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T20:30:22.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":2.78,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001588861-26-000002","document":"form4-06112026_040605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000158886126000002/form4-06112026_040605.xml","form_type":"4"}},{"id":741330,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39185,"kind":"person","name":"HALL WALLACE L JR","position":1,"cik":"0001762801","reported_name":"HALL WALLACE L JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T20:30:19.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":2.78,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001762801-26-000002","document":"form4-06112026_040615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000176280126000002/form4-06112026_040615.xml","form_type":"4"}},{"id":741413,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T20:30:17.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":2.78,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001201256-26-000003","document":"form4-06112026_040613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000120125626000003/form4-06112026_040613.xml","form_type":"4"}},{"id":924598,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":68186,"kind":"person","name":"O'Brien Stephen Paul","position":1,"cik":"0002064889","reported_name":"O'Brien Stephen Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-02T21:30:16.000Z","date":"2026-01-29","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest and become exercisable in equal monthly installments over 48 months commencing on January 29, 2026, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":15000,"derivative":{"exercise_price":3.9,"expiration_date":"2036-01-29","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0002064889-26-000002","document":"form4-02022026_040207.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000206488926000002/form4-02022026_040207.xml","form_type":"4"}},{"id":924597,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":68185,"kind":"person","name":"Conn Avi Daniel","position":1,"cik":"0002064982","reported_name":"Conn Avi Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-02T21:30:14.000Z","date":"2026-01-29","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest and become exercisable in equal monthly installments over 48 months commencing on January 29, 2026, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":45000,"derivative":{"exercise_price":3.9,"expiration_date":"2036-01-29","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0002064982-26-000002","document":"form4-02022026_040205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000206498226000002/form4-02022026_040205.xml","form_type":"4"}},{"id":924596,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":68184,"kind":"person","name":"Kauh John Saewook M.D.","position":1,"cik":"0002064881","reported_name":"Kauh John Saewook M.D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-02T21:30:13.000Z","date":"2026-01-29","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest and become exercisable in equal monthly installments over 48 months commencing on January 29, 2026, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":45000,"derivative":{"exercise_price":3.9,"expiration_date":"2036-01-29","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0002064881-26-000002","document":"form4-02022026_040203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000206488126000002/form4-02022026_040203.xml","form_type":"4"}},{"id":924594,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":68183,"kind":"person","name":"Alibhai Imran Nizamudin","position":1,"cik":"0002064884","reported_name":"Alibhai Imran Nizamudin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-02T21:30:11.000Z","date":"2026-01-29","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest and become exercisable in equal monthly installments over 48 months commencing on January 29, 2026, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":115000,"derivative":{"exercise_price":3.9,"expiration_date":"2036-01-29","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0002064884-26-000002","document":"form4-02022026_040201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000206488426000002/form4-02022026_040201.xml","form_type":"4"}},{"id":962920,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":68186,"kind":"person","name":"O'Brien Stephen Paul","position":1,"cik":"0002064889","reported_name":"O'Brien Stephen Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-18T22:00:14.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on December 16, 2026, and the balance of the shares subject to the option shall vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":4000,"derivative":{"exercise_price":4.2,"expiration_date":"2035-12-16","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0002064889-25-000003","document":"form4-12182025_051207.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000206488925000003/form4-12182025_051207.xml","form_type":"4"}},{"id":962919,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":68184,"kind":"person","name":"Kauh John Saewook M.D.","position":1,"cik":"0002064881","reported_name":"Kauh John Saewook M.D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-18T22:00:12.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on December 16, 2026, and the balance of the shares subject to the option shall vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":17500,"derivative":{"exercise_price":4.2,"expiration_date":"2035-12-16","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0002064881-25-000003","document":"form4-12182025_051205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000206488125000003/form4-12182025_051205.xml","form_type":"4"}},{"id":962918,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":68185,"kind":"person","name":"Conn Avi Daniel","position":1,"cik":"0002064982","reported_name":"Conn Avi Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-18T22:00:11.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on December 16, 2026, and the balance of the shares subject to the option shall vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":17500,"derivative":{"exercise_price":4.2,"expiration_date":"2035-12-16","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0002064982-25-000003","document":"form4-12182025_051203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000206498225000003/form4-12182025_051203.xml","form_type":"4"}},{"id":962917,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":68183,"kind":"person","name":"Alibhai Imran Nizamudin","position":1,"cik":"0002064884","reported_name":"Alibhai Imran Nizamudin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-18T22:00:04.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":47500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on December 16, 2026, and the balance of the shares subject to the option shall vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":47500,"derivative":{"exercise_price":4.2,"expiration_date":"2035-12-16","underlying":"Common Stock","underlying_shares":47500},"source":{"system":"sec-edgar","filing":"0002064884-25-000003","document":"form4-12182025_051201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000206488425000003/form4-12182025_051201.xml","form_type":"4"}},{"id":1074223,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":76884,"kind":"person","name":"Tweardy Samuel David","position":1,"cik":"0002066396","reported_name":"Tweardy Samuel David","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-06T00:03:49.000Z","date":"2025-07-07","kind":"other","planned":false,"acquired":false,"shares":315658,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person resigned as trustee of the family trust that directly holds the shares, as such the Reporting Person no longer retains any form beneficial ownership. The resignation does not constitute a sale of the of the shares and was permitted by the lock-up agreement by and between each family trust and the Issuer, dated December 17, 2024, and the shares remain subject to the lock-up agreement pursuant to the terms thereof."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person resigned as trustee of the family trust that directly holds the shares, as such the Reporting Person no longer retains any form beneficial ownership. The resignation does not constitute a sale of the of the shares and was permitted by the lock-up agreement by and between each family trust and the Issuer, dated December 17, 2024, and the shares remain subject to the lock-up agreement pursuant to the terms thereof."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-021100","document":"form4-08062025_120846.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925021100/form4-08062025_120846.xml","form_type":"4"}},{"id":1074222,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":76884,"kind":"person","name":"Tweardy Samuel David","position":1,"cik":"0002066396","reported_name":"Tweardy Samuel David","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-06T00:03:49.000Z","date":"2025-07-07","kind":"other","planned":false,"acquired":false,"shares":315658,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person resigned as trustee of the family trust that directly holds the shares, as such the Reporting Person no longer retains any form beneficial ownership. The resignation does not constitute a sale of the of the shares and was permitted by the lock-up agreement by and between each family trust and the Issuer, dated December 17, 2024, and the shares remain subject to the lock-up agreement pursuant to the terms thereof."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person resigned as trustee of the family trust that directly holds the shares, as such the Reporting Person no longer retains any form beneficial ownership. The resignation does not constitute a sale of the of the shares and was permitted by the lock-up agreement by and between each family trust and the Issuer, dated December 17, 2024, and the shares remain subject to the lock-up agreement pursuant to the terms thereof."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-021100","document":"form4-08062025_120846.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925021100/form4-08062025_120846.xml","form_type":"4"}},{"id":1160839,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39185,"kind":"person","name":"HALL WALLACE L JR","position":1,"cik":"0001762801","reported_name":"HALL WALLACE L JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-02T22:19:16.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":202044,"ownership":{"direct":false,"nature":"BioMatrix Partners Ltd."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The initial Form 4 inadvertently listed an incorrect transaction code."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 250,000 shares of Series A Preferred Stock of Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") pursuant to Agreement and Plan of Merger and Reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\") and 11,183 shares of common stock of Issuer issuable upon exchange of convertible notes of Tvardi in the principal amount of $250,000 plus accrued and unpaid interest, pursuant to the Merger Agreement and the terms of the convertible notes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for 1,000,000 shares of Series A Preferred Stock and 173,448 Series B Preferred Stock of Legacy Tvardi pursuant to the Merger Agreement and 44,665 shares of common stock of Issuer issuable upon exchange of convertible notes of Tvardi in the principal amount of $1,000,000 plus accrued and unpaid interest, pursuant to the Merger Agreement and the terms of the convertible notes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Reporting Person is a general partner of BioMatrix Partners Ltd. (\"BioMartix\") and may be deemed to share voting and dispositive power of the shares held by Biomatrix but disclaims beneficial ownership of the shares held by such entity except to any pecuniary interest therein."}],"balance_after":202044,"source":{"system":"sec-edgar","filing":"0001415889-25-011859","document":"form4a-05022025_100513.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925011859/form4a-05022025_100513.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1160838,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39185,"kind":"person","name":"HALL WALLACE L JR","position":1,"cik":"0001762801","reported_name":"HALL WALLACE L JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-02T22:19:16.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":44712,"ownership":{"direct":false,"nature":"Firepit Partners, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The initial Form 4 inadvertently listed an incorrect transaction code."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 250,000 shares of Series A Preferred Stock of Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") pursuant to Agreement and Plan of Merger and Reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\") and 11,183 shares of common stock of Issuer issuable upon exchange of convertible notes of Tvardi in the principal amount of $250,000 plus accrued and unpaid interest, pursuant to the Merger Agreement and the terms of the convertible notes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a general partner of Firepit Partners, LP (\"Firepit\") and may be deemed to share voting and dispositive power of the shares held by Firepit but disclaims beneficial ownership of the shares held by such entity except to any pecuniary interest therein."}],"balance_after":44712,"source":{"system":"sec-edgar","filing":"0001415889-25-011859","document":"form4a-05022025_100513.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925011859/form4a-05022025_100513.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1161421,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-02T18:12:20.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":263164,"ownership":{"direct":false,"nature":"Palkon TT Holdings, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The initial Form 4 inadvertently listed an incorrect transaction code."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for 1,962,199 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a Managing Manager of the Palkon Holdings LLC and Palkon TT Holdings LLC (the \"Palkon entities\"). The Reporting Person may be deemed to share the power to direct the disposition and vote of the shares held by the Palkon entities, but disclaims beneficial ownership, except to any pecuniary interests therein."}],"balance_after":263164,"source":{"system":"sec-edgar","filing":"0001415889-25-011857","document":"form4a-05022025_100517.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000141588925011857/form4a-05022025_100517.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1161420,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-02T18:12:20.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":176030,"ownership":{"direct":false,"nature":"Palkon Holdings, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The initial Form 4 inadvertently listed an incorrect transaction code."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for 1,312,508 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a Managing Manager of the Palkon Holdings LLC and Palkon TT Holdings LLC (the \"Palkon entities\"). The Reporting Person may be deemed to share the power to direct the disposition and vote of the shares held by the Palkon entities, but disclaims beneficial ownership, except to any pecuniary interests therein."}],"balance_after":176030,"source":{"system":"sec-edgar","filing":"0001415889-25-011857","document":"form4a-05022025_100517.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000141588925011857/form4a-05022025_100517.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1168259,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":80628,"kind":"person","name":"Larson Jeffrey Leroy","position":1,"cik":"0002064985","reported_name":"Larson Jeffrey Leroy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Research & Development"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-21T21:15:32.000Z","date":"2025-04-17","kind":"grant","planned":false,"acquired":true,"shares":10820,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on April 17, 2026, and the balance of the shares subject to the option shall vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":10820,"derivative":{"exercise_price":17.04,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":10820},"source":{"system":"sec-edgar","filing":"0001415889-25-011118","document":"form4-04212025_050428.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925011118/form4-04212025_050428.xml","form_type":"4"}},{"id":1168257,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":68186,"kind":"person","name":"O'Brien Stephen Paul","position":1,"cik":"0002064889","reported_name":"O'Brien Stephen Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-21T21:15:30.000Z","date":"2025-04-17","kind":"grant","planned":false,"acquired":true,"shares":7213,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on April 17, 2026, and the balance of the shares subject to the option shall vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":7213,"derivative":{"exercise_price":17.04,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":7213},"source":{"system":"sec-edgar","filing":"0001415889-25-011117","document":"form4-04212025_050426.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925011117/form4-04212025_050426.xml","form_type":"4"}},{"id":1168258,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":80627,"kind":"person","name":"Chen Yixin","position":1,"cik":"0002064987","reported_name":"Chen Yixin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chem, Mfg and Ctrls"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-21T21:15:27.000Z","date":"2025-04-17","kind":"grant","planned":false,"acquired":true,"shares":7213,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on April 17, 2026, and the balance of the shares subject to the option shall vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":7213,"derivative":{"exercise_price":17.04,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":7213},"source":{"system":"sec-edgar","filing":"0001415889-25-011116","document":"form4-04212025_050423.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925011116/form4-04212025_050423.xml","form_type":"4"}},{"id":1168256,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":68185,"kind":"person","name":"Conn Avi Daniel","position":1,"cik":"0002064982","reported_name":"Conn Avi Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-21T21:15:25.000Z","date":"2025-04-17","kind":"grant","planned":false,"acquired":true,"shares":43547,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on April 17, 2026, and the balance of the shares subject to the option shall vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":43547,"derivative":{"exercise_price":17.04,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":43547},"source":{"system":"sec-edgar","filing":"0001415889-25-011115","document":"form4-04212025_050421.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925011115/form4-04212025_050421.xml","form_type":"4"}},{"id":1168255,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":68184,"kind":"person","name":"Kauh John Saewook M.D.","position":1,"cik":"0002064881","reported_name":"Kauh John Saewook M.D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-21T21:15:22.000Z","date":"2025-04-17","kind":"grant","planned":false,"acquired":true,"shares":36210,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on April 17, 2026, and the balance of the shares subject to the option shall vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":36210,"derivative":{"exercise_price":17.04,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":36210},"source":{"system":"sec-edgar","filing":"0001415889-25-011114","document":"form4-04212025_050418.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925011114/form4-04212025_050418.xml","form_type":"4"}},{"id":1168254,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":68183,"kind":"person","name":"Alibhai Imran Nizamudin","position":1,"cik":"0002064884","reported_name":"Alibhai Imran Nizamudin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-21T21:15:20.000Z","date":"2025-04-17","kind":"grant","planned":false,"acquired":true,"shares":182320,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on April 17, 2026, and the balance of the shares subject to the option shall vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":182320,"derivative":{"exercise_price":17.04,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":182320},"source":{"system":"sec-edgar","filing":"0001415889-25-011113","document":"form4-04212025_050416.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925011113/form4-04212025_050416.xml","form_type":"4"}},{"id":1168440,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39305,"kind":"person","name":"Shiff Susan Ph.D.","position":1,"cik":"0001811463","reported_name":"Shiff Susan Ph.D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-21T21:15:17.000Z","date":"2025-04-17","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest and become exercisable over three years in 12 equal quarterly installments commencing on July 17, 2025, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":12000,"derivative":{"exercise_price":17.04,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001415889-25-011112","document":"form4-04212025_050413.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811463/000141588925011112/form4-04212025_050413.xml","form_type":"4"}},{"id":1168271,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-21T21:15:12.000Z","date":"2025-04-17","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest and become exercisable over three years in 12 equal quarterly installments commencing on July 17, 2025, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":12000,"derivative":{"exercise_price":17.04,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001415889-25-011110","document":"form4-04212025_050409.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000141588925011110/form4-04212025_050409.xml","form_type":"4"}},{"id":1168253,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":35382,"kind":"person","name":"Smith Cynthia","position":1,"cik":"0001609480","reported_name":"Smith Cynthia","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-21T21:15:11.000Z","date":"2025-04-17","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest and become exercisable over three years in 12 equal quarterly installments commencing on July 17, 2025, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":12000,"derivative":{"exercise_price":17.04,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001415889-25-011109","document":"form4-04212025_050406.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925011109/form4-04212025_050406.xml","form_type":"4"}},{"id":1168252,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-21T21:15:08.000Z","date":"2025-04-17","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest and become exercisable over three years in 12 equal quarterly installments commencing on July 17, 2025, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":12000,"derivative":{"exercise_price":17.04,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001415889-25-011108","document":"form4-04212025_050404.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925011108/form4-04212025_050404.xml","form_type":"4"}},{"id":1168247,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39185,"kind":"person","name":"HALL WALLACE L JR","position":1,"cik":"0001762801","reported_name":"HALL WALLACE L JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-21T21:15:05.000Z","date":"2025-04-17","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest and become exercisable over three years in 12 equal quarterly installments commencing on July 17, 2025, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":12000,"derivative":{"exercise_price":17.04,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001415889-25-011107","document":"form4-04212025_050401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925011107/form4-04212025_050401.xml","form_type":"4"}},{"id":1168518,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-21T17:15:15.000Z","date":"2025-04-17","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest and become exercisable over three years in 12 equal quarterly installments commencing on July 17, 2025, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":12000,"derivative":{"exercise_price":17.04,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001415889-25-011111","document":"form4-04212025_050411.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000141588925011111/form4-04212025_050411.xml","form_type":"4"}},{"id":1169525,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":68186,"kind":"person","name":"O'Brien Stephen Paul","position":1,"cik":"0002064889","reported_name":"O'Brien Stephen Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-17T22:50:22.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":3352,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for a stock option to acquire 25,000 shares of common stock of Legacy Tvardi with the exercise price of $0.92 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vested or will vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date."}],"balance_after":3352,"derivative":{"exercise_price":6.86,"expiration_date":"2034-01-30","underlying":"Common Stock","underlying_shares":3352},"source":{"system":"sec-edgar","filing":"0001415889-25-010985","document":"form4-04172025_060419.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925010985/form4-04172025_060419.xml","form_type":"4"}},{"id":1169524,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":68186,"kind":"person","name":"O'Brien Stephen Paul","position":1,"cik":"0002064889","reported_name":"O'Brien Stephen Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-17T22:50:22.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":11399,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for a stock option to acquire 85,000 shares of common stock of Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") with the exercise price of $0.63 per share pursuant to an Agreement and Plan of Merger and reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vested or will vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date."}],"balance_after":11399,"derivative":{"exercise_price":4.7,"expiration_date":"2031-12-15","underlying":"Common Stock","underlying_shares":11399},"source":{"system":"sec-edgar","filing":"0001415889-25-010985","document":"form4-04172025_060419.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925010985/form4-04172025_060419.xml","form_type":"4"}},{"id":1169522,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39185,"kind":"person","name":"HALL WALLACE L JR","position":1,"cik":"0001762801","reported_name":"HALL WALLACE L JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T22:50:20.000Z","date":"2025-04-15","kind":"other","planned":false,"acquired":true,"shares":202044,"ownership":{"direct":false,"nature":"BioMatrix Partners Ltd."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Received in exchange for 1,000,000 shares of Series A Preferred Stock and 173,448 Series B Preferred Stock of Legacy Tvardi pursuant to the Merger Agreement and 44,665 shares of common stock of Issuer issuable upon exchange of convertible notes of Tvardi in the principal amount of $1,000,000 plus accrued and unpaid interest, pursuant to the Merger Agreement and the terms of the convertible notes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 250,000 shares of Series A Preferred Stock of Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") pursuant to Agreement and Plan of Merger and Reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\") and 11,183 shares of common stock of Issuer issuable upon exchange of convertible notes of Tvardi in the principal amount of $250,000 plus accrued and unpaid interest, pursuant to the Merger Agreement and the terms of the convertible notes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a general partner of BioMatrix Partners Ltd. (\"BioMartix\") and may be deemed to share voting and dispositive power of the shares held by Biomatrix but disclaims beneficial ownership of the shares held by such entity except to any pecuniary interest therein."}],"balance_after":202044,"source":{"system":"sec-edgar","filing":"0001415889-25-010984","document":"form4-04172025_060417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925010984/form4-04172025_060417.xml","form_type":"4"}},{"id":1169521,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39185,"kind":"person","name":"HALL WALLACE L JR","position":1,"cik":"0001762801","reported_name":"HALL WALLACE L JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T22:50:20.000Z","date":"2025-04-15","kind":"other","planned":false,"acquired":true,"shares":44712,"ownership":{"direct":false,"nature":"Firepit Partners, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Received in exchange for 250,000 shares of Series A Preferred Stock of Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") pursuant to Agreement and Plan of Merger and Reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\") and 11,183 shares of common stock of Issuer issuable upon exchange of convertible notes of Tvardi in the principal amount of $250,000 plus accrued and unpaid interest, pursuant to the Merger Agreement and the terms of the convertible notes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 250,000 shares of Series A Preferred Stock of Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") pursuant to Agreement and Plan of Merger and Reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\") and 11,183 shares of common stock of Issuer issuable upon exchange of convertible notes of Tvardi in the principal amount of $250,000 plus accrued and unpaid interest, pursuant to the Merger Agreement and the terms of the convertible notes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a general partner of Firepit Partners, LP (\"Firepit\") and may be deemed to share voting and dispositive power of the shares held by Firepit but disclaims beneficial ownership of the shares held by such entity except to any pecuniary interest therein."}],"balance_after":44712,"source":{"system":"sec-edgar","filing":"0001415889-25-010984","document":"form4-04172025_060417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925010984/form4-04172025_060417.xml","form_type":"4"}},{"id":1169520,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":68184,"kind":"person","name":"Kauh John Saewook M.D.","position":1,"cik":"0002064881","reported_name":"Kauh John Saewook M.D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-17T22:50:19.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":74049,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for a stock option to acquire 552,129 shares of common stock of Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") with the exercise price of $0.82 per share pursuant to an Agreement and Plan of Merger and reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vested or will vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date."}],"balance_after":74049,"derivative":{"exercise_price":6.12,"expiration_date":"2031-12-15","underlying":"Common Stock","underlying_shares":74049},"source":{"system":"sec-edgar","filing":"0001415889-25-010983","document":"form4-04172025_060415.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925010983/form4-04172025_060415.xml","form_type":"4"}},{"id":1169579,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-17T22:50:16.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":18441,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for a stock option to acquire 137,500 shares of common stock of Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") with the exercise price of $0.63 per share pursuant to an Agreement and Plan of Merger and reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vested or will vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date."}],"balance_after":18441,"derivative":{"exercise_price":4.7,"expiration_date":"2031-12-15","underlying":"Common Stock","underlying_shares":18441},"source":{"system":"sec-edgar","filing":"0001415889-25-010982","document":"form4-04172025_060413.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000141588925010982/form4-04172025_060413.xml","form_type":"4"}},{"id":1169519,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":80627,"kind":"person","name":"Chen Yixin","position":1,"cik":"0002064987","reported_name":"Chen Yixin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chem, Mfg and Ctrls"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-17T22:50:15.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":14752,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for a stock option to acquire 110,000 shares of common stock of Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") with the exercise price of $0.63 per share pursuant to an Agreement and Plan of Merger and reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vested or will vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date."}],"balance_after":14752,"derivative":{"exercise_price":4.7,"expiration_date":"2031-12-15","underlying":"Common Stock","underlying_shares":14752},"source":{"system":"sec-edgar","filing":"0001415889-25-010981","document":"form4-04172025_060411.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925010981/form4-04172025_060411.xml","form_type":"4"}},{"id":1169518,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-17T22:50:11.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":8047,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for a stock option to acquire 60,000 shares of common stock of Legacy Tvardi with the exercise price of $0.63 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vested or will vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date."}],"balance_after":8047,"derivative":{"exercise_price":4.7,"expiration_date":"2031-12-15","underlying":"Common Stock","underlying_shares":8047},"source":{"system":"sec-edgar","filing":"0001415889-25-010979","document":"form4-04172025_060407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925010979/form4-04172025_060407.xml","form_type":"4"}},{"id":1169517,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-17T22:50:11.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":10394,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for a stock option to acquire 77,500 shares of common stock of Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") with the exercise price of $0.09 per share pursuant to an Agreement and Plan of Merger and Reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested and exercisable."}],"balance_after":10394,"derivative":{"exercise_price":0.68,"expiration_date":"2031-01-29","underlying":"Common Stock","underlying_shares":10394},"source":{"system":"sec-edgar","filing":"0001415889-25-010979","document":"form4-04172025_060407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925010979/form4-04172025_060407.xml","form_type":"4"}},{"id":1169516,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":80628,"kind":"person","name":"Larson Jeffrey Leroy","position":1,"cik":"0002064985","reported_name":"Larson Jeffrey Leroy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Research & Development"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-17T22:50:09.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":5364,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for a stock option to acquire 40,000 shares of common stock of Legacy Tvardi with the exercise price of $0.63 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vested or will vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date."}],"balance_after":5364,"derivative":{"exercise_price":4.7,"expiration_date":"2031-12-15","underlying":"Common Stock","underlying_shares":5364},"source":{"system":"sec-edgar","filing":"0001415889-25-010978","document":"form4-04172025_060405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925010978/form4-04172025_060405.xml","form_type":"4"}},{"id":1169515,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":80628,"kind":"person","name":"Larson Jeffrey Leroy","position":1,"cik":"0002064985","reported_name":"Larson Jeffrey Leroy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Research & Development"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-17T22:50:09.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":16764,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for a stock option to acquire 125,000 shares of common stock of Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") with the exercise price of $0.09 per share pursuant to an Agreement and Plan of Merger and Reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested and exercisable."}],"balance_after":16764,"derivative":{"exercise_price":0.68,"expiration_date":"2031-01-29","underlying":"Common Stock","underlying_shares":16764},"source":{"system":"sec-edgar","filing":"0001415889-25-010978","document":"form4-04172025_060405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925010978/form4-04172025_060405.xml","form_type":"4"}},{"id":1169514,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":68185,"kind":"person","name":"Conn Avi Daniel","position":1,"cik":"0002064982","reported_name":"Conn Avi Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-17T22:50:06.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":89053,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for a stock option to acquire 664,000 shares of common stock of Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") with the exercise price of $0.63 per share pursuant to an Agreement and Plan of Merger and Reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vested or will vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date."}],"balance_after":89053,"derivative":{"exercise_price":4.7,"expiration_date":"2032-02-03","underlying":"Common Stock","underlying_shares":89053},"source":{"system":"sec-edgar","filing":"0001415889-25-010977","document":"form4-04172025_060403.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925010977/form4-04172025_060403.xml","form_type":"4"}},{"id":1169513,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":68183,"kind":"person","name":"Alibhai Imran Nizamudin","position":1,"cik":"0002064884","reported_name":"Alibhai Imran Nizamudin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-17T22:50:05.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":160940,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in exchange for a stock option to acquire 1,200,000 shares of common stock of Legacy Tvardi with the exercise price of $0.63 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vested or will vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date."}],"balance_after":160940,"derivative":{"exercise_price":4.7,"expiration_date":"2031-12-15","underlying":"Common Stock","underlying_shares":160940},"source":{"system":"sec-edgar","filing":"0001415889-25-010976","document":"form4-04172025_060401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925010976/form4-04172025_060401.xml","form_type":"4"}},{"id":1169512,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":68183,"kind":"person","name":"Alibhai Imran Nizamudin","position":1,"cik":"0002064884","reported_name":"Alibhai Imran Nizamudin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Optyion (right to buy)","published_at":"2025-04-17T22:50:05.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":2011,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in exchange for a stock option to acquire 15,000 shares of common stock of Legacy Tvardi with the exercise price of $0.09 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested and exercisable."}],"balance_after":2011,"derivative":{"exercise_price":0.68,"expiration_date":"2031-01-29","underlying":"Common Stock","underlying_shares":2011},"source":{"system":"sec-edgar","filing":"0001415889-25-010976","document":"form4-04172025_060401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925010976/form4-04172025_060401.xml","form_type":"4"}},{"id":1169511,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":68183,"kind":"person","name":"Alibhai Imran Nizamudin","position":1,"cik":"0002064884","reported_name":"Alibhai Imran Nizamudin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-17T22:50:05.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":207881,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for a stock option to acquire 1,550,000 shares of common stock of Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") with the exercise price of $0.09 per share pursuant to an Agreement and Plan of Merger and Reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested and exercisable."}],"balance_after":207881,"derivative":{"exercise_price":0.68,"expiration_date":"2029-01-15","underlying":"Common Stock","underlying_shares":207881},"source":{"system":"sec-edgar","filing":"0001415889-25-010976","document":"form4-04172025_060401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925010976/form4-04172025_060401.xml","form_type":"4"}},{"id":1170018,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-17T18:50:13.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":2011,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received in exchange for a stock option to acquire 15,000 shares of common stock of Legacy Tvardi with the exercise price of $0.09 per share pursuant the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Under the terms of the Merger, with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully vested and exercisable."}],"balance_after":2011,"derivative":{"exercise_price":0.68,"expiration_date":"2031-01-29","underlying":"Common Stock","underlying_shares":2011},"source":{"system":"sec-edgar","filing":"0001415889-25-010980","document":"form4-04172025_060409.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000141588925010980/form4-04172025_060409.xml","form_type":"4"}},{"id":1170017,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T18:50:13.000Z","date":"2025-04-15","kind":"other","planned":false,"acquired":true,"shares":263164,"ownership":{"direct":false,"nature":"Palkon TT Holdings, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Received in exchange for 1,962,199 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for 1,962,199 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a Managing Manager of the Palkon Holdings LLC and Palkon TT Holdings LLC (the \"Palkon entities\"). The Reporting Person may be deemed to share the power to direct the disposition and vote of the shares held by the Palkon entities, but disclaims beneficial ownership, except to any pecuniary interests therein."}],"balance_after":263164,"source":{"system":"sec-edgar","filing":"0001415889-25-010980","document":"form4-04172025_060409.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000141588925010980/form4-04172025_060409.xml","form_type":"4"}},{"id":1170016,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T18:50:13.000Z","date":"2025-04-15","kind":"other","planned":false,"acquired":true,"shares":176030,"ownership":{"direct":false,"nature":"Palkon Holdings, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Received in exchange for 1,312,508 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for 1,312,508 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a Managing Manager of the Palkon Holdings LLC and Palkon TT Holdings LLC (the \"Palkon entities\"). The Reporting Person may be deemed to share the power to direct the disposition and vote of the shares held by the Palkon entities, but disclaims beneficial ownership, except to any pecuniary interests therein."}],"balance_after":176030,"source":{"system":"sec-edgar","filing":"0001415889-25-010980","document":"form4-04172025_060409.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000141588925010980/form4-04172025_060409.xml","form_type":"4"}},{"id":1170015,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T18:50:13.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":4191,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 31,252 shares of Series B Preferred Stock of  Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") pursuant to Agreement and Plan of Merger and Reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."}],"balance_after":4191,"source":{"system":"sec-edgar","filing":"0001415889-25-010980","document":"form4-04172025_060409.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000141588925010980/form4-04172025_060409.xml","form_type":"4"}},{"id":1227148,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":82427,"kind":"person","name":"Posner Christopher","position":1,"cik":"0001748265","reported_name":"Posner Christopher","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2025-03-04T21:59:22.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":583,"price":4.75,"value":2769.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":13109,"source":{"system":"sec-edgar","filing":"0001415889-25-006576","document":"form4-03042025_090317.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925006576/form4-03042025_090317.xml","form_type":"4"}},{"id":1227146,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":82426,"kind":"person","name":"Terrillion Scott","position":1,"cik":"0001706426","reported_name":"Terrillion Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEC'Y; CHIEF COMPLIANCE & G.C."}}],"security":"Common Stock","published_at":"2025-03-04T21:58:32.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":163,"price":4.76,"value":775.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on September 7, 2018 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The total number of securities reported as beneficially owned following the reported transaction reflects the 1-for-12 reverse stock split that was effected by the Issuer on December 30, 2024."}],"balance_after":7190,"source":{"system":"sec-edgar","filing":"0001415889-25-006575","document":"form4-03042025_090329.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925006575/form4-03042025_090329.xml","form_type":"4"}},{"id":1280123,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":82427,"kind":"person","name":"Posner Christopher","position":1,"cik":"0001748265","reported_name":"Posner Christopher","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2025-02-07T00:15:34.000Z","date":"2025-02-04","kind":"sale","planned":false,"acquired":false,"shares":372,"price":4.72,"value":1755.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.72 to $4.74 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The total number of securities reported as beneficially owned following the reported transaction reflects the 1-for-12 reverse stock split that was effected by the Issuer on December 30, 2024."}],"balance_after":13692,"source":{"system":"sec-edgar","filing":"0001415889-25-003295","document":"form4-02072025_120231.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925003295/form4-02072025_120231.xml","form_type":"4"}},{"id":1374042,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":82427,"kind":"person","name":"Posner Christopher","position":1,"cik":"0001748265","reported_name":"Posner Christopher","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-11-06T21:51:22.000Z","date":"2024-11-04","kind":"sale","planned":false,"acquired":false,"shares":3668,"price":0.29,"value":1063.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."}],"balance_after":168768,"source":{"system":"sec-edgar","filing":"0001415889-24-026248","document":"form4-11062024_091118.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588924026248/form4-11062024_091118.xml","form_type":"4"}},{"id":1442592,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":82427,"kind":"person","name":"Posner Christopher","position":1,"cik":"0001748265","reported_name":"Posner Christopher","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-08-02T20:05:11.000Z","date":"2024-08-01","kind":"sale","planned":false,"acquired":false,"shares":4149,"price":0.35,"value":1452.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."}],"balance_after":172436,"source":{"system":"sec-edgar","filing":"0001415889-24-020605","document":"form4-08022024_040806.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588924020605/form4-08022024_040806.xml","form_type":"4"}},{"id":1488413,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30995,"kind":"person","name":"Boudreau Helen M","position":1,"cik":"0001661481","reported_name":"Boudreau Helen M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:28:07.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":195000,"derivative":{"exercise_price":0.664,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0001415889-24-015765","document":"form4-06062024_080604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1661481/000141588924015765/form4-06062024_080604.xml","form_type":"4"}},{"id":1488412,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30995,"kind":"person","name":"Boudreau Helen M","position":1,"cik":"0001661481","reported_name":"Boudreau Helen M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T20:28:07.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":150647,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares underlying restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":150647,"source":{"system":"sec-edgar","filing":"0001415889-24-015765","document":"form4-06062024_080604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661481/000141588924015765/form4-06062024_080604.xml","form_type":"4"}},{"id":1489098,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:26:51.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":195000,"derivative":{"exercise_price":0.664,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0001415889-24-015763","document":"form4-06062024_080647.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000141588924015763/form4-06062024_080647.xml","form_type":"4"}},{"id":1489097,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T20:26:51.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":150647,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares underlying restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":183009,"source":{"system":"sec-edgar","filing":"0001415889-24-015763","document":"form4-06062024_080647.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000141588924015763/form4-06062024_080647.xml","form_type":"4"}},{"id":1488140,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":40807,"kind":"person","name":"Ives Jeffrey L.","position":1,"cik":"0001614096","reported_name":"Ives Jeffrey L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:25:40.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":195000,"derivative":{"exercise_price":0.664,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0001415889-24-015760","document":"form4-06062024_080636.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588924015760/form4-06062024_080636.xml","form_type":"4"}},{"id":1488139,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":40807,"kind":"person","name":"Ives Jeffrey L.","position":1,"cik":"0001614096","reported_name":"Ives Jeffrey L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T20:25:40.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":150647,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares underlying restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":198485,"source":{"system":"sec-edgar","filing":"0001415889-24-015760","document":"form4-06062024_080636.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588924015760/form4-06062024_080636.xml","form_type":"4"}},{"id":1488556,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39305,"kind":"person","name":"Shiff Susan Ph.D.","position":1,"cik":"0001811463","reported_name":"Shiff Susan Ph.D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:24:29.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":195000,"derivative":{"exercise_price":0.664,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0001415889-24-015756","document":"form4-06062024_080626.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811463/000141588924015756/form4-06062024_080626.xml","form_type":"4"}},{"id":1488555,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39305,"kind":"person","name":"Shiff Susan Ph.D.","position":1,"cik":"0001811463","reported_name":"Shiff Susan Ph.D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T20:24:29.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":150647,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares underlying restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":202085,"source":{"system":"sec-edgar","filing":"0001415889-24-015756","document":"form4-06062024_080626.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811463/000141588924015756/form4-06062024_080626.xml","form_type":"4"}},{"id":1488200,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":90194,"kind":"person","name":"VOGELBAUM MARTIN","position":1,"cik":"0001237624","reported_name":"VOGELBAUM MARTIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T16:22:30.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":390000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":390000,"derivative":{"exercise_price":0.664,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":390000},"source":{"system":"sec-edgar","filing":"0001415889-24-015751","document":"form4-06062024_080626.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237624/000141588924015751/form4-06062024_080626.xml","form_type":"4"}},{"id":1488199,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":90194,"kind":"person","name":"VOGELBAUM MARTIN","position":1,"cik":"0001237624","reported_name":"VOGELBAUM MARTIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T16:22:30.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":301295,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares underlying restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":411007,"source":{"system":"sec-edgar","filing":"0001415889-24-015751","document":"form4-06062024_080626.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237624/000141588924015751/form4-06062024_080626.xml","form_type":"4"}},{"id":1526077,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":82427,"kind":"person","name":"Posner Christopher","position":1,"cik":"0001748265","reported_name":"Posner Christopher","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-05-06T20:15:59.000Z","date":"2024-05-02","kind":"sale","planned":false,"acquired":false,"shares":3936,"price":0.75,"value":2952.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.75 to $0.76 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":176585,"source":{"system":"sec-edgar","filing":"0001415889-24-012322","document":"form4-05062024_040544.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588924012322/form4-05062024_040544.xml","form_type":"4"}},{"id":1544577,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":23083,"kind":"person","name":"Goncalves Joana","position":1,"cik":"0001756991","reported_name":"Goncalves Joana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-04-09T20:22:02.000Z","date":"2024-04-05","kind":"sale","planned":false,"acquired":false,"shares":2753,"price":0.83,"value":2284.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on March 12, 2020 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."}],"balance_after":53365,"source":{"system":"sec-edgar","filing":"0001415889-24-010570","document":"form4-04092024_080455.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1756991/000141588924010570/form4-04092024_080455.xml","form_type":"4"}},{"id":1544378,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":82426,"kind":"person","name":"Terrillion Scott","position":1,"cik":"0001706426","reported_name":"Terrillion Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEC'Y; CHIEF COMPLIANCE & G.C."}}],"security":"Common Stock","published_at":"2024-04-09T20:21:00.000Z","date":"2024-04-05","kind":"sale","planned":false,"acquired":false,"shares":2753,"price":0.83,"value":2284.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on September 7, 2018 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."}],"balance_after":88247,"source":{"system":"sec-edgar","filing":"0001415889-24-010569","document":"form4-04092024_080453.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588924010569/form4-04092024_080453.xml","form_type":"4"}},{"id":1602557,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":82426,"kind":"person","name":"Terrillion Scott","position":1,"cik":"0001706426","reported_name":"Terrillion Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEC'Y; CHIEF COMPLIANCE & G.C."}}],"security":"Common Stock","published_at":"2024-03-04T21:24:57.000Z","date":"2024-02-29","kind":"sale","planned":false,"acquired":false,"shares":3293,"price":0.89,"value":2930.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on September 7, 2018 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."}],"balance_after":91000,"source":{"system":"sec-edgar","filing":"0001415889-24-006282","document":"form4-03042024_090307.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588924006282/form4-03042024_090307.xml","form_type":"4"}},{"id":1602558,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":82427,"kind":"person","name":"Posner Christopher","position":1,"cik":"0001748265","reported_name":"Posner Christopher","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-03-04T21:19:05.000Z","date":"2024-02-29","kind":"sale","planned":false,"acquired":false,"shares":5834,"price":0.89,"value":5192.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."}],"balance_after":180521,"source":{"system":"sec-edgar","filing":"0001415889-24-006273","document":"form4-03042024_090323.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588924006273/form4-03042024_090323.xml","form_type":"4"}},{"id":1603302,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":23083,"kind":"person","name":"Goncalves Joana","position":1,"cik":"0001756991","reported_name":"Goncalves Joana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-04T21:13:52.000Z","date":"2024-02-29","kind":"sale","planned":false,"acquired":false,"shares":3293,"price":0.89,"value":2930.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on March 12, 2020 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."}],"balance_after":56118,"source":{"system":"sec-edgar","filing":"0001415889-24-006265","document":"form4-03042024_090307.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1756991/000141588924006265/form4-03042024_090307.xml","form_type":"4"}},{"id":1648857,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":82426,"kind":"person","name":"Terrillion Scott","position":1,"cik":"0001706426","reported_name":"Terrillion Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEC'Y; CHIEF COMPLIANCE & G.C."}}],"security":"Common Stock","published_at":"2024-02-12T22:16:39.000Z","date":"2023-02-08","kind":"sale","planned":false,"acquired":false,"shares":7770,"price":0.53,"value":4118.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on September 7, 2018 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."}],"balance_after":94293,"source":{"system":"sec-edgar","filing":"0001415889-24-003408","document":"form4-02122024_100232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588924003408/form4-02122024_100232.xml","form_type":"4"}},{"id":1648856,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":36777,"kind":"person","name":"Maynard Ryan D","position":1,"cik":"0001363984","reported_name":"Maynard Ryan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-12T22:15:08.000Z","date":"2023-02-08","kind":"sale","planned":true,"acquired":false,"shares":5488,"price":0.53,"value":2908.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on September 14, 2023 accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."}],"balance_after":8012,"source":{"system":"sec-edgar","filing":"0001415889-24-003404","document":"form4-02122024_100201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588924003404/form4-02122024_100201.xml","form_type":"4"}},{"id":1649393,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":23083,"kind":"person","name":"Goncalves Joana","position":1,"cik":"0001756991","reported_name":"Goncalves Joana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-12T22:13:39.000Z","date":"2023-02-08","kind":"sale","planned":false,"acquired":false,"shares":7770,"price":0.53,"value":4118.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on March 12, 2020 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."}],"balance_after":59411,"source":{"system":"sec-edgar","filing":"0001415889-24-003400","document":"form4-02122024_100214.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1756991/000141588924003400/form4-02122024_100214.xml","form_type":"4"}},{"id":1648855,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":82427,"kind":"person","name":"Posner Christopher","position":1,"cik":"0001748265","reported_name":"Posner Christopher","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-02-12T22:10:31.000Z","date":"2024-02-08","kind":"sale","planned":false,"acquired":false,"shares":35575,"price":0.53,"value":18854.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."}],"balance_after":186355,"source":{"system":"sec-edgar","filing":"0001415889-24-003395","document":"form4-02122024_100215.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588924003395/form4-02122024_100215.xml","form_type":"4"}},{"id":1658387,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":82426,"kind":"person","name":"Terrillion Scott","position":1,"cik":"0001706426","reported_name":"Terrillion Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEC'Y; CHIEF COMPLIANCE & G.C."}}],"security":"Common Stock","published_at":"2024-02-05T21:34:12.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares that vested under a performance-based restricted stock unit award (the \"Award\") granted on March 1, 2023 based on the Issuer's satisfaction of certain performance criteria of the Award. In light of the performance-based vesting conditions of the Award, such shares were not reportable under Section 16 until vesting was determined. On February 1, 2024, the Compensation Committee of the Issuer's Board of Directors certified a 50% level of achievement against the Award's performance goals."}],"balance_after":102063,"source":{"system":"sec-edgar","filing":"0001415889-24-002536","document":"form4-02052024_090253.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588924002536/form4-02052024_090253.xml","form_type":"4"}},{"id":1658386,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":36777,"kind":"person","name":"Maynard Ryan D","position":1,"cik":"0001363984","reported_name":"Maynard Ryan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-05T21:32:05.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares that vested under a performance-based restricted stock unit award (the \"Award\") granted on March 1, 2023 based on the Issuer's satisfaction of certain performance criteria of the Award. In light of the performance-based vesting conditions of the Award, such shares were not reportable under Section 16 until vesting was determined. On February 1, 2024, the Compensation Committee of the Issuer's Board of Directors certified a 50% level of achievement against the Award's performance goals."}],"balance_after":13500,"source":{"system":"sec-edgar","filing":"0001415889-24-002528","document":"form4-02052024_090254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588924002528/form4-02052024_090254.xml","form_type":"4"}},{"id":1659002,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":23083,"kind":"person","name":"Goncalves Joana","position":1,"cik":"0001756991","reported_name":"Goncalves Joana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-05T21:30:21.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares that vested under a performance-based restricted stock unit award (the \"Award\") granted on March 1, 2023 based on the Issuer's satisfaction of certain performance criteria of the Award. In light of the performance-based vesting conditions of the Award, such shares were not reportable under Section 16 until vesting was determined. On February 1, 2024, the Compensation Committee of the Issuer's Board of Directors certified a 50% level of achievement against the Award's performance goals."}],"balance_after":67181,"source":{"system":"sec-edgar","filing":"0001415889-24-002522","document":"form4-02052024_090202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1756991/000141588924002522/form4-02052024_090202.xml","form_type":"4"}},{"id":1658385,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":94604,"kind":"person","name":"Menzaghi Frederique Ph.D.","position":1,"cik":"0001597152","reported_name":"Menzaghi Frederique Ph.D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFF,SVP-R&D"}}],"security":"Common Stock","published_at":"2024-02-05T21:28:07.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares that vested under a performance-based restricted stock unit award (the \"Award\") granted on March 1, 2023 based on the Issuer's satisfaction of certain performance criteria of the Award. In light of the performance-based vesting conditions of the Award, such shares were not reportable under Section 16 until vesting was determined. On February 1, 2024, the Compensation Committee of the Issuer's Board of Directors certified a 50% level of achievement against the Award's performance goals."}],"balance_after":167247,"source":{"system":"sec-edgar","filing":"0001415889-24-002515","document":"form4-02052024_090257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588924002515/form4-02052024_090257.xml","form_type":"4"}},{"id":1658384,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":82427,"kind":"person","name":"Posner Christopher","position":1,"cik":"0001748265","reported_name":"Posner Christopher","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-02-05T21:26:05.000Z","date":"2024-02-01","kind":"sale","planned":false,"acquired":false,"shares":4981,"price":0.55,"value":2739.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":221930,"source":{"system":"sec-edgar","filing":"0001415889-24-002513","document":"form4-02052024_090257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588924002513/form4-02052024_090257.xml","form_type":"4"}},{"id":1658383,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":82427,"kind":"person","name":"Posner Christopher","position":1,"cik":"0001748265","reported_name":"Posner Christopher","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-02-05T21:26:05.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares that vested under a performance-based restricted stock unit award (the \"Award\") granted on March 1, 2023 based on the Issuer's satisfaction of certain performance criteria of the Award. In light of the performance-based vesting conditions of the Award, such shares were not reportable under Section 16 until vesting was determined. On February 1, 2024, the Compensation Committee of the Issuer's Board of Directors certified a 50% level of achievement against the Award's performance goals."}],"balance_after":226911,"source":{"system":"sec-edgar","filing":"0001415889-24-002513","document":"form4-02052024_090257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588924002513/form4-02052024_090257.xml","form_type":"4"}},{"id":1749469,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":82427,"kind":"person","name":"Posner Christopher","position":1,"cik":"0001748265","reported_name":"Posner Christopher","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-11-03T20:37:53.000Z","date":"2023-11-02","kind":"sale","planned":false,"acquired":false,"shares":3796,"price":1.22,"value":4631.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."}],"balance_after":164411,"source":{"system":"sec-edgar","filing":"0001209191-23-054332","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919123054332/doc4.xml","form_type":"4"}},{"id":1814745,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":82427,"kind":"person","name":"Posner Christopher","position":1,"cik":"0001748265","reported_name":"Posner Christopher","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-08-04T21:21:53.000Z","date":"2023-08-03","kind":"sale","planned":true,"acquired":false,"shares":4307,"price":3.07,"value":13222.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.07 to $3.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":168207,"source":{"system":"sec-edgar","filing":"0001209191-23-044636","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919123044636/doc4.xml","form_type":"4"}},{"id":1814951,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30995,"kind":"person","name":"Boudreau Helen M","position":1,"cik":"0001661481","reported_name":"Boudreau Helen M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-04T21:20:52.000Z","date":"2023-08-02","kind":"grant","planned":false,"acquired":true,"shares":155747,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in twelve (12) equal quarterly installments beginning on August 2, 2023 such that the option will be fully vested and exercisable on August 2, 2026, subject to the Reporting Person's continued service to the Issuer on each such date."}],"balance_after":155747,"derivative":{"exercise_price":3.09,"expiration_date":"2033-08-02","underlying":"Common Stock","underlying_shares":155747},"source":{"system":"sec-edgar","filing":"0001209191-23-044635","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661481/000120919123044635/doc4.xml","form_type":"4"}},{"id":1843310,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":82426,"kind":"person","name":"Terrillion Scott","position":1,"cik":"0001706426","reported_name":"Terrillion Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sec'y; Chief Compliance & G.C."}}],"security":"Common Stock","published_at":"2023-06-27T20:09:18.000Z","date":"2023-06-23","kind":"sale","planned":true,"acquired":false,"shares":2483,"price":3.51,"value":8715.33,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on September 7, 2018 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."}],"balance_after":88563,"source":{"system":"sec-edgar","filing":"0001209191-23-039884","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919123039884/doc4.xml","form_type":"4"}},{"id":1843309,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":94604,"kind":"person","name":"Menzaghi Frederique Ph.D.","position":1,"cik":"0001597152","reported_name":"Menzaghi Frederique Ph.D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Off,SVP-R&D"}}],"security":"Common Stock","published_at":"2023-06-27T20:08:11.000Z","date":"2023-06-23","kind":"sale","planned":true,"acquired":false,"shares":2993,"price":3.51,"value":10505.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on September 5, 2018 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.51 to $3.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":153747,"source":{"system":"sec-edgar","filing":"0001209191-23-039883","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919123039883/doc4.xml","form_type":"4"}},{"id":1843503,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":23083,"kind":"person","name":"Goncalves Joana","position":1,"cik":"0001756991","reported_name":"Goncalves Joana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-06-27T20:07:03.000Z","date":"2023-06-23","kind":"sale","planned":true,"acquired":false,"shares":2723,"price":3.51,"value":9557.73,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on March 12, 2020 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.45 to $3.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":53681,"source":{"system":"sec-edgar","filing":"0001209191-23-039882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1756991/000120919123039882/doc4.xml","form_type":"4"}},{"id":1868337,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-05T20:36:25.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":44961,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":44961,"derivative":{"exercise_price":3.09,"expiration_date":"2033-06-01","underlying":"Common Stock","underlying_shares":44961},"source":{"system":"sec-edgar","filing":"0001209191-23-034341","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000120919123034341/doc4.xml","form_type":"4"}},{"id":1868336,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T20:36:25.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":32362,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares underlying restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest  on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":32362,"source":{"system":"sec-edgar","filing":"0001209191-23-034341","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000120919123034341/doc4.xml","form_type":"4"}},{"id":1867309,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39305,"kind":"person","name":"Shiff Susan Ph.D.","position":1,"cik":"0001811463","reported_name":"Shiff Susan Ph.D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-05T20:34:32.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":44961,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":44961,"derivative":{"exercise_price":3.09,"expiration_date":"2033-06-01","underlying":"Common Stock","underlying_shares":44961},"source":{"system":"sec-edgar","filing":"0001209191-23-034330","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811463/000120919123034330/doc4.xml","form_type":"4"}},{"id":1867308,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39305,"kind":"person","name":"Shiff Susan Ph.D.","position":1,"cik":"0001811463","reported_name":"Shiff Susan Ph.D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T20:34:32.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":32362,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares underlying restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest  on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":51438,"source":{"system":"sec-edgar","filing":"0001209191-23-034330","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811463/000120919123034330/doc4.xml","form_type":"4"}},{"id":1866475,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":40807,"kind":"person","name":"Ives Jeffrey L.","position":1,"cik":"0001614096","reported_name":"Ives Jeffrey L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-05T20:33:22.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":44961,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":44961,"derivative":{"exercise_price":3.09,"expiration_date":"2033-06-01","underlying":"Common Stock","underlying_shares":44961},"source":{"system":"sec-edgar","filing":"0001209191-23-034327","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919123034327/doc4.xml","form_type":"4"}},{"id":1866474,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":40807,"kind":"person","name":"Ives Jeffrey L.","position":1,"cik":"0001614096","reported_name":"Ives Jeffrey L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T20:33:22.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":32362,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares underlying restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest  on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":47838,"source":{"system":"sec-edgar","filing":"0001209191-23-034327","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919123034327/doc4.xml","form_type":"4"}},{"id":1866562,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":17680,"kind":"person","name":"BAINS HARRISON M JR","position":1,"cik":"0001202282","reported_name":"BAINS HARRISON M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-05T16:31:05.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":44961,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":44961,"derivative":{"exercise_price":3.09,"expiration_date":"2033-06-01","underlying":"Common Stock","underlying_shares":44961},"source":{"system":"sec-edgar","filing":"0001209191-23-034322","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1202282/000120919123034322/doc4.xml","form_type":"4"}},{"id":1866561,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":17680,"kind":"person","name":"BAINS HARRISON M JR","position":1,"cik":"0001202282","reported_name":"BAINS HARRISON M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T16:31:05.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":32362,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares underlying restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest  on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":57438,"source":{"system":"sec-edgar","filing":"0001209191-23-034322","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202282/000120919123034322/doc4.xml","form_type":"4"}},{"id":1866644,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":90194,"kind":"person","name":"VOGELBAUM MARTIN","position":1,"cik":"0001237624","reported_name":"VOGELBAUM MARTIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-05T16:29:25.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":89923,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":89923,"derivative":{"exercise_price":3.09,"expiration_date":"2033-06-01","underlying":"Common Stock","underlying_shares":89923},"source":{"system":"sec-edgar","filing":"0001209191-23-034300","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237624/000120919123034300/doc4.xml","form_type":"4"}},{"id":1866643,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":90194,"kind":"person","name":"VOGELBAUM MARTIN","position":1,"cik":"0001237624","reported_name":"VOGELBAUM MARTIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T16:29:25.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":64724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares underlying restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest  on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":109712,"source":{"system":"sec-edgar","filing":"0001209191-23-034300","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237624/000120919123034300/doc4.xml","form_type":"4"}},{"id":1899279,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":82427,"kind":"person","name":"Posner Christopher","position":1,"cik":"0001748265","reported_name":"Posner Christopher","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-05-09T20:22:31.000Z","date":"2023-05-05","kind":"sale","planned":true,"acquired":false,"shares":3869,"price":4.4,"value":17023.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."}],"balance_after":172514,"source":{"system":"sec-edgar","filing":"0001209191-23-028247","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919123028247/doc4.xml","form_type":"4"}},{"id":1923571,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":82426,"kind":"person","name":"Terrillion Scott","position":1,"cik":"0001706426","reported_name":"Terrillion Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sec'y; Chief Compliance & G.C."}}],"security":"Common Stock","published_at":"2023-04-06T21:14:33.000Z","date":"2023-04-04","kind":"sale","planned":false,"acquired":false,"shares":2481,"price":4.91,"value":12181.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.84 to $4.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":91046,"source":{"system":"sec-edgar","filing":"0001209191-23-023607","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919123023607/doc4.xml","form_type":"4"}},{"id":1923822,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":23083,"kind":"person","name":"Goncalves Joana","position":1,"cik":"0001756991","reported_name":"Goncalves Joana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-04-06T21:13:41.000Z","date":"2023-04-04","kind":"sale","planned":false,"acquired":false,"shares":2481,"price":4.91,"value":12181.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.82 to $4.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":56404,"source":{"system":"sec-edgar","filing":"0001209191-23-023606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1756991/000120919123023606/doc4.xml","form_type":"4"}}],"next_cursor":"2023-04-06T21:13:41.000000Z,1923822"}